Crossmark

Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era

Published Online: 2021-07-10

Published Print: 2022-06

Authors

Allahham, Mahmoud https://orcid.org/0000-0002-2990-106X
Lerman, A.

Atar, D.

Birnbaum, Y.
License Information

Text and Data Mining valid from 2021-07-10

Version of Record valid from 2021-07-10
More Information

Article History

Accepted: 29 June 2021

First Online: 10 July 2021

Declarations

:

: Mahmoud Allahham, MD: None.Amir Lerman, MD: consulting fee—Philips/Volcano and Itamar medical.Dan Atar, MD: None.Yochai Birnbaum, MD: research grant—AstraZeneca.

Document is current